Cellumed Co.,Ltd. (KOSDAQ:049180)

South Korea · Delayed Price · Currency is KRW

1,009.00

-101.00 (-9.10%)

At close: Mar 16, 2026

-29.93% (1Y)

Market Cap	83.94B +13.2%
Revenue (ttm)	124.37B -12.5%
Net Income	-2.45B
EPS	-40.78
Shares Out	83.19M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,744,448
Open	1,111.00
Previous Close	1,110.00
Day's Range	950.00 - 1,126.00
52-Week Range	542.00 - 2,975.00
Beta	1.41
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 21, 2026

About Cellumed

Cellumed Co.,Ltd., a biotechnology company, provides bone graft materials, medical devices, and cosmeceuticals in South Korea. The company offers CLnZyme, a mRNA enzyme; cosmeceuticals, such as FGF7 for skin regeneration and TGFβ-1 for tissue regeneration; and electric motorcycles. It provides tissue bank products, such as celluderm powder, ultra, and HD implant for the skin; patellar tendon hemi whole, posterior tibialis, anterior tibialis, semitendinosus, gracilis, and peroneus longus tendons, and meniscus lateral and medial; cancellous bone ... [Read more]

Industry Business Services, not elsewhere classified

Founded 1985

Employees 90

Stock Exchange KOSDAQ

Ticker Symbol 049180

Full Company Profile

Financial Performance

In 2025, Cellumed's revenue was 140.19 billion, an increase of 8.56% compared to the previous year's 129.14 billion. Losses were -2.24 billion, -92.91% less than in 2024.

Financial Statements